Slide of the Month Archive
March 2011 Optimal times for between-agency dialogue
April 2011 Lowest number of NAS approvals in 2010 by both FDA and EMA in ten years
May 2011 Seven steps in the benefit-risk assessment of medicines
July 2011 Impact of priority, accelerated, and fast-track review status on US FDA approval times
September 2011 The percentage of NASs approved by CDER by one-cycle review process has increased
November 2011 Regulatory review process: what are enablers?
December 2011 Key factors likely to impact medicines development